|
rs1045642
|
|
|
0.060 |
GeneticVariation |
BEFREE |
BRCA1 rs1799966 minor allele C (TC+CC vs. TT, OR = 0.402, 95% CI = 0.204-0.794, p = 0.008) and MDR1/ABCB1 rs1045642 minor allele A (GA +AA vs. GG, OR = 0.478, 95% CI = 0.244-0.934, p = 0.030) were associated with a better response to chemotherapy in advanced NSCLC patients.
|
24933103 |
2014 |
|
rs1045642
|
|
|
0.060 |
GeneticVariation |
BEFREE |
MDR1 single nucleotide polymorphism C3435T in Turkish patients with non-small-cell lung cancer.
|
22766400 |
2012 |
|
rs1045642
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Polymorphisms of ERCC1 C118T/C8092A and MDR1 C3435T predict outcome of platinum-based chemotherapies in advanced non-small cell lung cancer: a meta-analysis.
|
21827803 |
2011 |
|
rs1045642
|
|
|
0.060 |
GeneticVariation |
BEFREE |
In this study we investigated the potential association of MDR1 2677G>T at exon 21, 3435C>T at exon 26 and their haplotypes with chemotherapy response of 54 Han Chinese patients with NSCLC.
|
18812689 |
2009 |
|
rs1045642
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Our findings suggest that MDR1 2677G-->T/A and 3435C-->T polymorphisms can be used to predict treatment response to VC chemotherapy in NSCLC patients.
|
17851225 |
2008 |
|
rs1045642
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Using the TaqMan 5' nuclease assay, we examined ERCC1 118, XPD 751 and 312, RRM1 -37C/A, and MDR1 C3435T SNPs in peripheral blood lymphocytes (PBLs) obtained from 62 docetaxel-cisplatin-treated advanced NSCLC patients.
|
15277258 |
2004 |
|
rs201661522
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Osimertinib is an irreversible EGFR inhibitor registered for advanced NSCLC patients whose tumors harbor recurrent somatic activating mutations in EGFR (EGFRm<sup>+</sup>) or the frequently occurring EGFR-T790M resistance mutation.
|
31175939 |
2019 |
|
rs201661522
|
|
|
0.020 |
GeneticVariation |
BEFREE |
It is approved for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, and for patients with T790M-positive advanced NSCLC whose disease has progressed on or after EGFR-TKI therapy.
|
30875094 |
2019 |
|
rs979090956
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Attention should be paid to MDR1 C3435T, G2677A/T and GSTP1 A313G for personalized chemotherapy treatment for NSCLC patients in Asian population in the future.
|
22761669 |
2012 |
|
rs2032582
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our findings suggest that the MDR1 2677G>T/A polymorphism and the 2677G-3435C haplotype are predictors of treatment response to docetaxel-cisplatin chemotherapy in NSCLC patients.
|
18812689 |
2009 |